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Diabetes Care: Making a Good Journal
Better
A
s I begin my 4th year as Editor-in-
Chief of Diabetes Care, I remain
proud of the achievements of our
editorial team and the tremendous suc-
cess of the journal. In addition, as I take
on additional roles in the American Dia-
betes Association (ADA), I am conscious
of the importance of the ADA’s mission in
providingthehighestqualityscientiﬁcin-
formation to the world. In that regard, we
are pleased that the journal remains very
high in the rankings in terms of reader-
ship, subscriptions, and citations, despite
a large number of new journals in the
ﬁeld. The journal’s impact factor remains
high,anditcontinuestoberatedasfourth
amongjournalsinendocrinologyandme-
tabolism. With the large number of inter-
national editions in several languages,
Diabetes Care is clearly established as the
leading clinical and clinical research jour-
nal worldwide in the ﬁeld of diabetes.
Last year we were concerned about a
small decline in the number of articles
submitted to us. I am pleased that this
trend was reversed in 2009. I hope it
means more support for clinical research
as we continue in our quest to ﬁnd a cure
for diabetes and improve the lives of
peoplewhosufferfromthiscondition.Un-
fortunately, for many the increase in sub-
missions also means a lower acceptance
rate,nowaround18%.Manygoodpapers
willinevitablyberejectedbecausewemay
be forced to give higher priority to other
competing papers. We continue to have a
broad range of clinically relevant papers
that will rapidly impact practice and clin-
ical research in the ﬁeld.
Despite our success, we need to look
for ways to make Diabetes Care better and
stronger, not only its scientiﬁc content
butalsoinissuesrelatingtoethics,policy,
and societal priorities. The ADA Publica-
tion Policy Committee continues to issue
important guidelines in respect to these
matters, and I will only touch on some of
these issues with my own personal views
(which are not necessarily the policies of
ADA).
We must be transparent at all levels
(authors, reviewers, and editors) in rela-
tiontoconﬂictsofinterest—whetherthey
are real or perceived. We have a separate
review/editorial process for handling pa-
pers when an associate editor is an author
or has a conﬂict. Given that health care is
in many ways a business, research is de-
pendent on funding; in our system, the
development of new treatments will al-
waysbelinkedtoproﬁts.Substantialclin-
ical research that is most likely to impact
patient care is funded by industry. Be-
cause of this, some conﬂict of interest is
inevitable. My personal view is that it is
not necessarily a bad thing since individ-
ualswiththegreatestlevelofexpertiseare
more likely to be consulted by those who
have a commercial interest in developing
new treatments. Must we shy away from
such conﬂicts completely as some of our
colleagues suggest? Not if we all have the
common goal of improving the lives of
our patients, whether or not a few proﬁt
from such success more than others. De-
spite some controversy about the value of
new drugs and their side effects (whether
based on anecdotes or good data), diabe-
tes control has improved dramatically in
the last 10–15 years as we have advanced
from having 2 drugs to prescribe to over
10 drugs today. What is important is that
we must be transparent in declaring such
conﬂictssothatreaderscandeterminefor
themselves whether there is a possible
bias in reporting results and their inter-
pretations. Guidelines on trial registra-
tion, publication policies, etc., have been
establishedandcontinuetoevolveandbe
reﬁned. It is also important to recognize
that conﬂicts are not exclusively ﬁnancial
and professional factors, such as compe-
tition for grant funding, career advance-
ment, etc., which may also represent an
important but intangible conﬂict—an is-
sue the purists seem to ignore.
Frequently in the news is the issue of
“ghostwriting” articles, particularly when
the author is supported by the pharma-
ceutical industry. Again, transparency
would eliminate all such accusations. We
recognize that large multicenter trials,
where authors are often in different cities
or even countries, may require an appro-
priate person to be paid to coordinate ef-
forts in analyzing data and preparing the
ﬁnal paper. Nevertheless, such efforts
need to be declared and these coordina-
tors and writers given credit for their
work. It is particularly important that
the lead authors on any paper play a sig-
niﬁcant role in the preparation of the ﬁrst
draft and that all authors play a role
in the ﬁnalization of a paper prior to
submission.
Who is an author and how many do
we need on a paper? This is a frequent
question that arises in relation to papers
from multicenter studies. The deﬁnition
of authorship has been very clearly laid
out numerous times in the literature, and
I will not repeat the criteria here. Clearly,
it is imperative that each named author
plays a signiﬁcant role in at least one as-
pect of the study (design, conduct, anal-
ysis,andinterpretation).AtDiabetesCare,
welimitthenumberofauthorsto12,and
it is extremely rare that a paper needs
more than that number to be true “au-
thors.” On the other hand, recognition
needs to be given to the many other play-
ers in multicenter trials. Toward that
end, we have now developed links to our
online appendix so that every person
listed in the online appendix is also listed
as an author on PubMed.
Finally, we continue to have a short-
age of reviewers who are both qualiﬁed
and willing to help us make decisions
about papers. More importantly, our re-
viewers help shape the ﬁnal version of
what we ultimately publish to the highest
possible level, which is what our readers
expect. In 2009, there were only 1,313
active reviewers from of a list of 5,295
potentialreviewerswhoagreedtoassistin
the review process. Once again, I feel the
need to remind all of our readers, partic-
ularly previous Diabetes Care authors, of
their responsibility to participate in the
peer review process. We ask that review-
ers be constructive in their criticism al-
lowing authors to revise their papers to
much higher standards for resubmission
either to us or elsewhere. Constructive
criticism will therefore greatly enhance
the standards of all journals and help in-
vestigatorsﬁrmtheirideasinamorelucid
manner.Wehaverevisedourinstructions
to reviewers asking for brief bulleted con-
structive points to be given to authors
rather than long diatribes. We now offer
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(CME) credits and hope that it will serve
as an incentive for potential reviewers.
Our associate editor team has under-
gonesomechangesoverthepastyear.We
thank Marian Rewers and Ann Nettles for
their long and valuable service and wel-
come Richard Pratley, Carla Greenbaum,
andKatieWeinger.Wealsothankandsay
goodbye to editorial board members
George L. Bakris, Verdain Barnes, Paresh
Dandona, Andreas Festa, Linda B. Haas,
Michele Heisler, Frank Hu, Takashi Kad-
owaki, Lawrence Lavery, and Merri Pen-
dergrass and welcome our new board
members.
Wehaveanoutstandingteamhelping
me to make this good journal better. Di-
abetesCarefunctionsuniquelyandwellin
a virtual world from an ofﬁce in Indiana
linked to the ADA ofﬁces in Virginia. Our
editorial team of Lyn Reynolds, Shannon
Potts, Jane Lucas, Rita Summers, and
Amanda Nixon now work with not only
Diabetes Care but also Diabetes, thus ful-
ﬁllingtheADA’simportantroleinthedis-
semination of the best basic and clinical
scientiﬁc information in an efﬁcient and
user-friendly manner. Every small step
makes our good journal outstanding.
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